| scholarly article | Q13442814 |
| P2093 | author name string | J D Scott | |
| D J Lancaster | |||
| D P Haghighat | |||
| J C Gathe | |||
| J H Sampson | |||
| J Spotkov | |||
| M N Dohn | |||
| P T Caldwell | |||
| R A Torres | |||
| R D Meyer | |||
| S C Deresinski | |||
| S E Follansbee | |||
| W G Weinberg | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| pentamidine | Q416206 | ||
| Pneumocystis carinii | Q2099992 | ||
| P304 | page(s) | 174-80 | |
| P577 | publication date | 1994-08-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group | |
| P478 | volume | 121 |
| Q34107885 | Antiparasitic agent atovaquone |
| Q92124647 | Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation |
| Q40432267 | Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections |
| Q91592473 | Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling |
| Q41331963 | Drug treatment of HIV-related opportunistic infections |
| Q52305103 | Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia. |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q34011311 | HIV: treating Pneumocystis pneumonia (PCP) |
| Q35557252 | Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions |
| Q33693150 | Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group |
| Q26795592 | Pneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future Directions |
| Q39417008 | Pneumocystis jirovecii colonization in Chronic Obstructive Pulmonary Disease (COPD). |
| Q38245616 | Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis |
| Q37180338 | Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066) |
Search more.